Literature DB >> 16709835

Reduced KIR2DL1 recognition of MHC class I molecules presenting phosphorylated peptides.

Gili Betser-Cohen1, Gil Katz, Tsufit Gonen-Gross, Noam Stern, Tal I Arnon, Hagit Achdout, Roi Gazit, Ofer Mandelboim.   

Abstract

As initially described by K. Karre and colleagues in the missing self hypothesis, cells expressing self-MHC class I proteins are protected from NK cells attack. In contrast, reduction in the expression of MHC class I molecules due to viral infection or tumor transformation result in the killing of these "abnormal" cells by NK cells via NK-activating receptors. Thus, NK killing of target cells is determined by both negative signals coming from MHC class I proteins and by positive signals derived from the activating ligands. The bound peptide in MHC class I play an important role in the balanced recognition of NK cells. The peptide stabilizes the MHC complex and interacts directly with the NK inhibitory receptors, thus participating in the determination of the fate of the target cells. In this study we demonstrate that posttranslational modifications such as phosphorylation of the presented peptide altered the ability of NK cells to recognize MHC class I molecules. By using a consensus peptide (QYDDAVYKL) that binds HLA-Cw4 in which different positions in the bound peptide were modified by serine phosphorylation, we observed a reduction in KIR2DL1 binding that led to decreased protection from NK killing. Therefore, it might be possible that alteration in the phosphorylation pattern during tumor transformation or viral infection may result in less inhibition and, consequently, improved NK cell killing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709835     DOI: 10.4049/jimmunol.176.11.6762

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.

Authors:  J R Vidal-Castiñeira; A López-Vázquez; R Díaz-Peña; R Alonso-Arias; J Martínez-Borra; R Pérez; J Fernández-Suárez; S Melón; J Prieto; L Rodrigo; C López-Larrea
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

2.  Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes.

Authors:  Jan Petersen; Stephanie J Wurzbacher; Nicholas A Williamson; Sri H Ramarathinam; Hugh H Reid; Ashish K N Nair; Anne Y Zhao; Roza Nastovska; Geordie Rudge; Jamie Rossjohn; Anthony W Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

Review 3.  Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Authors:  Dong-Rui Wang; Xian-Lin Wu; Ying-Li Sun
Journal:  Signal Transduct Target Ther       Date:  2022-09-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.